MX2016013332A - Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas. - Google Patents

Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.

Info

Publication number
MX2016013332A
MX2016013332A MX2016013332A MX2016013332A MX2016013332A MX 2016013332 A MX2016013332 A MX 2016013332A MX 2016013332 A MX2016013332 A MX 2016013332A MX 2016013332 A MX2016013332 A MX 2016013332A MX 2016013332 A MX2016013332 A MX 2016013332A
Authority
MX
Mexico
Prior art keywords
human
cell receptors
binding human
immunoglobulins binding
cells
Prior art date
Application number
MX2016013332A
Other languages
English (en)
Spanish (es)
Inventor
Jelle Van Der Vliet Johannes
Cornelia Gerarda DE BRUIN Renée
Denise De Gruijl Tanja
Marinus Willem VERHEUL Hendrik
Original Assignee
Stichting Vumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vumc filed Critical Stichting Vumc
Publication of MX2016013332A publication Critical patent/MX2016013332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2016013332A 2014-04-10 2015-04-10 Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas. MX2016013332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2012604 2014-04-10
PCT/NL2015/050235 WO2015156673A1 (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Publications (1)

Publication Number Publication Date
MX2016013332A true MX2016013332A (es) 2017-05-01

Family

ID=50896416

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013332A MX2016013332A (es) 2014-04-10 2015-04-10 Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
MX2021009674A MX2021009674A (es) 2014-04-10 2016-10-10 Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009674A MX2021009674A (es) 2014-04-10 2016-10-10 Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.

Country Status (11)

Country Link
US (4) US10501540B2 (zh)
EP (1) EP3129404A1 (zh)
JP (4) JP6617138B2 (zh)
KR (2) KR102359264B1 (zh)
CN (2) CN106536557B (zh)
AU (3) AU2015244489B2 (zh)
CA (1) CA2948812A1 (zh)
EA (2) EA039086B1 (zh)
MX (2) MX2016013332A (zh)
SG (2) SG11201609417VA (zh)
WO (1) WO2015156673A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10356636B2 (en) * 2017-04-03 2019-07-16 Qualcomm Incorporated Techniques and apparatuses to improve drone-mounted user equipment performance
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
CN112703201A (zh) * 2018-07-05 2021-04-23 诺沃班德畜牧业治疗公司 针对家禽致病原的抗体和其用途
US20220111043A1 (en) 2018-09-19 2022-04-14 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
WO2020146393A1 (en) 2019-01-07 2020-07-16 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
US20220135694A1 (en) 2019-02-01 2022-05-05 Lava Therapeutics B.V. Novel cd40-binding antibodies
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
JP7308477B2 (ja) * 2019-03-11 2023-07-14 パナソニックＩｐマネジメント株式会社 抗体、複合体、それを用いた検出装置及び検出方法
MX2021013532A (es) * 2019-05-08 2022-02-11 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t.
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
WO2022008646A1 (en) 2020-07-08 2022-01-13 LAVA Therapeutics N.V. Antibodies that bind psma and gamma-delta t cell receptors
CN116390950A (zh) * 2020-10-28 2023-07-04 詹森生物科技公司 用于调节δγ链介导的免疫的组合物和方法
JP2023547520A (ja) 2020-11-05 2023-11-10 メンドゥス・ベスローテン・フェンノートシャップ 免疫療法における腫瘍非依存性抗原の使用
EP4257617A1 (en) * 2020-12-01 2023-10-11 Cure Genetics Co., Ltd Antigen-binding protein targeting cd70 and use thereof
EP4259660A1 (en) 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
CA3209454A1 (en) 2021-02-26 2022-09-01 Robertus Cornelis ROOVERS Antibodies that bind cd123 and gamma-delta t cell receptors
KR20240055002A (ko) 2021-09-13 2024-04-26 얀센 바이오테크 인코포레이티드 암 치료를 위한 CD33 x Vδ2 다중특이성 항체
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
TW202334233A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 結合γδ T細胞之多肽及其用途
CN115043936B (zh) * 2022-03-31 2023-06-27 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN116178538A (zh) * 2023-01-05 2023-05-30 暨南大学 靶向热休克蛋白70的纳米抗体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
EP1627231A2 (en) * 2003-05-23 2006-02-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improvements to gamma delta t cell-mediated therapy
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
US8012466B2 (en) * 2008-01-31 2011-09-06 University Of Iowa Research Foundation Immunogenic compositions for activating γδ T cells
CN102154205A (zh) * 2011-01-31 2011-08-17 郑骏年 高纯度、高细胞毒活性的γδT细胞的制备方法
AU2013201422B2 (en) * 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (zh) * 2012-02-10 2015-05-13 深圳市合一康生物科技股份有限公司 一种人γδT细胞的形态学、纯度及免疫表型检测方法
US9891211B2 (en) 2012-03-28 2018-02-13 Gadeta B.V. Gamma 9 delta 2 T cell receptors

Also Published As

Publication number Publication date
JP2022136078A (ja) 2022-09-15
US10501540B2 (en) 2019-12-10
CN113105550A (zh) 2021-07-13
KR20170019343A (ko) 2017-02-21
KR102601469B1 (ko) 2023-11-14
US20230212290A1 (en) 2023-07-06
US11384145B2 (en) 2022-07-12
JP6617138B2 (ja) 2019-12-11
CN106536557A (zh) 2017-03-22
EA202192165A1 (ru) 2021-12-31
AU2015244489A1 (en) 2016-12-01
US20220098301A1 (en) 2022-03-31
JP2020029461A (ja) 2020-02-27
EA039086B1 (ru) 2021-12-01
AU2023204215A1 (en) 2023-07-20
US20170029506A1 (en) 2017-02-02
KR102359264B1 (ko) 2022-02-04
SG10202007233TA (en) 2020-09-29
JP7094931B2 (ja) 2022-07-04
KR20220021015A (ko) 2022-02-21
AU2020213325B2 (en) 2023-03-30
EP3129404A1 (en) 2017-02-15
US20190263908A1 (en) 2019-08-29
SG11201609417VA (en) 2016-12-29
JP7342202B2 (ja) 2023-09-11
CA2948812A1 (en) 2015-10-15
WO2015156673A1 (en) 2015-10-15
AU2020213325A1 (en) 2020-08-27
JP2023165723A (ja) 2023-11-17
AU2015244489B2 (en) 2020-08-27
MX2021009674A (es) 2021-09-08
JP2017513521A (ja) 2017-06-01
CN106536557B (zh) 2021-05-04
EA201692039A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2021009674A (es) Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
IL251292A0 (en) Bispecific antigen binding molecules activate t cells against folr1 and cd3
PH12018501882A1 (en) Binding proteins and methods of use thereof
AU2017240801A8 (en) Chimeric receptors to FLT3 and methods of use thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
LT3789402T (lt) Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12020552229A1 (en) Il-11ra antibodies
BR112018068678A2 (pt) anticorpos anti-mica
TW201614072A (en) CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
UY33492A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PH12014502179A1 (en) Ang2-binding molecules
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MX2016010953A (es) Proteinas de fc multimericas.
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
JOP20190101A1 (ar) أنظمة علاج
WO2014172653A3 (en) Anti-notch1 antibodies
MY181915A (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases